News | November 10, 2010

FDA Gives Update on CT Brain Scan Investigation


November 10, 2010 – The U.S. Food and Drug Administration (FDA) has concluded that radiation over-exposure during computed tomography (CT) scans was due to user error, not the scanner manufacturers. The finding comes after the FDA investigated more than 300 reports of over-exposure during brain perfusion scans.

The scanners involved were manufactured by GE Healthcare and Toshiba America Medical Systems. Inspectors found there were no violations of FDA laws and regulations. The FDA evaluated the specifications for multislice CT scanners and found when they were used properly, they did not result in overexposure. The FDA also reviewed literature that supports that the manufacturer-defined protocols do provide reasonable and appropriate image quality and dose. Investigators said there is no evidence the manufacturers were involved in modifying any of the hospitals’ scanning protocols to cause the overexposures.

However, the investigation did reveal improvements the industry could make to improve the safety of their equipment and reduce the likelihood of overexposures.

In 2009, the FDA began investigating complaints about radiation overexposure of 206 patients at the Cedars-Sinai Medical Center. As of Oct. 26, 2010, the agency is aware of approximately 385 patients from six hospitals who were exposed to excess radiation during CT brain perfusion scans.

The FDA said a typical radiation dose of 0.5 Gy is expected for a CT brain perfusion scan.

The American Association of Physicists in Medicine (AAPM) is working with CT manufacturers to specify exam protocols. This includes specialty exams such as brain perfusion studies, which may require relatively higher doses.

The FDA encouraged CT facilities to review their protocols and make sure that the values displayed on the control panel corresponded to the doses normally associated with the protocol.

Additionally, the FDA said that CT operators should be specifically trained on dose-saving features such as automatic exposure control (AEC) before using them. If the user activates AEC without reviewing and adjusting the associated parameters, the default values could lead to an overexposure.

For more information: www.aapm.org/pubs/CTProtocols, www.fda.gov


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now